Medical/Pharmaceuticals

Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment

* Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...

2025-08-26 14:29 1699

Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids

SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA)...

2025-08-26 11:47 1830

Fullerton Health Announces Strategic Investment by Mitsubishi Corporation

SINGAPORE, Aug. 26, 2025 /PRNewswire/ -- Fullerton Health Pte. Ltd. ("Fullerton Health" or the "Company"), a leading healthcare solutions provider operating in nine markets acrossAsia-Pacific, today announced that Mitsubishi Corporation has acquired a strategic minority stake in the Company. This...

2025-08-26 10:00 1838

Infinitus Named in Liaowang Institution's "Leading Transparent Factory Case Studies"

GUANGZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Amid the digital economy and shifting consumer expectations, "trust" has become a core driver of sustainable business growth. The "Transparent Factory • Building the Future with Trust — 2025 Trust Productivity High-End Dialogue" was held in Jiangmen...

2025-08-26 02:55 2241

Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®

Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...

2025-08-26 02:10 1502

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....

2025-08-25 21:18 2863

Everest Medicines Announces Participation in September Investor Conferences

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...

2025-08-25 20:57 1643

Peijia Medical Announces 2025 Interim Results

HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months endedJune 30, 2025 ("the Reporting Period") on August 22...

2025-08-25 20:00 2241

Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial

NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...

2025-08-25 18:27 1745

Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment ofFrancis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and ...

2025-08-25 16:42 1615

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

* The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 * DEEs ar...

2025-08-25 15:43 1203

Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints

HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study ...

2025-08-25 13:46 1325

Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts

EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility inWaltham, Massachusetts to fur...

2025-08-25 12:01 1486

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment...

2025-08-25 09:00 1914

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimm...

2025-08-25 08:00 1774

Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform

* The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression level...

2025-08-22 18:14 2529

Heartbeats Launches Digital Wellness Platform Led by World-Renowned Heart Specialist Dr. Hosen Kiat

SYDNEY, Aug. 22, 2025 /PRNewswire/ -- In an online world awash with wellness fads and misinformation, one of the world's most cited cardiologists has decided to step in.Dr Hosen Kiat , ranked among the top 1% of clinical researchers worldwide, has launched aYouTube

2025-08-22 13:22 2026

MALAYSIA SHOWCASES HEALTHCARE EXCELLENCE IN CAMBODIA, DRIVING MOMENTUM TOWARDS MYMT 2026

KUALA LUMPUR, Malaysia, Aug. 22, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) proudly presents Malaysia Healthcare Week 2025 inPhnom Penh, Cambodia, an initiative designed to strengthening healthcare ties between the two nations and positionMalaysia as the medical tourism de...

2025-08-22 11:00 2778

Biosyngen Unveils Innovative Strategies for Next-Generation TIL Therapies in Asia Bio 2025 Singapore

SINGAPORE, Aug. 22, 2025 /PRNewswire/ -- Asia Bio Innovation Summit 2025 is one of the premier industry-focused events inAsia and focus on the hottest topics of ADC and CGT. Asia Bio Innovation summit 2025 Singapore brought together 30+ world-class Speakers, 10+ Exhibitors and 200+ Attendees from...

2025-08-22 09:55 2877

Doceree launches Premium Programmatic adding more context, more reach, and more formats to traditional HCP programmatic

* With Premium Programmatic, pharma marketers can now engage physicians across 2,000+ integrated specialist medical platforms delivering clinically aligned content at scale with unmatched precision and exclusive formats. SHORT HILLS, N.J., Aug. 21, 2025 /PRNewswire/ -- Doceree, the only AI-powe...

2025-08-21 21:32 2201
1 ... 45464748495051 ... 644

Week's Top Stories